Skip to main content
SpringerLink
Log in

Antidementiva

  • Chapter
Book cover Arzneiverordnungs-Report 2007

Auszug

Cholinesterasehemmer und Memantin zeigen 2006 einen weiteren Verordnungszuwachs und haben jetzt einen Anteil von 50% am Verordnungsvolumen der Antidementiva erreicht. Traditionelle Antidementiva (Sekalealkaloide, Piracetam, Ginkgoextrakt) haben dagegen ihren rückläufigen Trend fortgesetzt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • AD2000 Collaborative Group (2004): Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 363:2105–2115.

    Article  CAS  Google Scholar 

  • Aguero-Torres H, Fratiglioni L, Winblad B (1998): Natural history of Alzheimer’s disease and other dementias: review of the literature in the light of the findings from the Kungsholmen Project. Int J Geriatr Psychiatry 13: 755–766.

    Article  PubMed  CAS  Google Scholar 

  • Bickel H (2001): Demenzen im höheren Lebensalter: Schätzungen des Vorkommens und der Versorgungskosten. Z Gerontol Geriat 34: 108–115.

    Article  CAS  Google Scholar 

  • Birks J (2006): Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006 Jan 25;(l):CD005593.

    Google Scholar 

  • Birks J, Grimley Evans J (2006): Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD003120.

    Google Scholar 

  • Birks J, Harvey RJ (2006): Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD001190.

    Google Scholar 

  • Birks J, Iakovidou V, Tsolaki M (2000): Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2: CD001191.

    PubMed  Google Scholar 

  • Blennow K, de Leon MJ, Zetterberg H (2006): Alzheimer’s disease. Lancet 368: 387–403.

    Article  PubMed  CAS  Google Scholar 

  • Committee for Proprietary Medicinal Products (CPMP) (1998): Note for guidance on medicinal products in the treatment of Alzheimer’s disease.

    Google Scholar 

  • Corey-Bloom J, Anand R, Veach J for the ENA 713 B352 Study Group (1998): A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1: 55–65.

    CAS  Google Scholar 

  • Croisile B, Trillet M, Fondarai J, Laurent B, Mauguière F, Billardon M (1993): Longterm and high-dose piracetam treatment of Alzheimer’s disease. Neurology 43: 301–305.

    PubMed  CAS  Google Scholar 

  • Davies P, Maloney AJ (1976): Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2: 1403.

    Article  PubMed  CAS  Google Scholar 

  • Dodel RC, Hampel H, Du Y (2003): Immunotherapy for Alzheimer’s disease. Lancet Neurology 2: 215–220.

    Article  PubMed  CAS  Google Scholar 

  • Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A et al. (2004): Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 75: 1472–1474.

    Article  PubMed  CAS  Google Scholar 

  • Dyer C (2007): NICE faces legal challenge over Alzheimer’s drug. BMJ 334: 654–655.

    Article  PubMed  Google Scholar 

  • Fioravanti M, Flicker L (2001): Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev 2001 (4): CD003159.

    PubMed  Google Scholar 

  • Flicker L, Grimley Evans G (2001): Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2001;(2):CD001011.

    PubMed  Google Scholar 

  • Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M (2005): Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64: 1563–1572.

    Article  PubMed  CAS  Google Scholar 

  • Gaitz CM, Varner RV, Overall JE (1977): Pharmacotherapy for organic brain syndrome in late life. Evaluation of an ergot derivative vs placebo. Arch Gen Psychiatry 34: 839–845.

    PubMed  CAS  Google Scholar 

  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2007): Nutzenbewertung von Cholinesterasehemmern bei Patienten mit Alzheimer Demenz, auch im Vergleich mit anderen Therapieoptionen. Im Internet unter: www.iqwig.de/download/A05-19A_Abschlussbericht_Cholinesterasehemmer_bei_Alzheimer_Demenz.pdf

    Google Scholar 

  • In’t Veld BA, Riutenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T et al (2001): Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 345: 1515–1521.

    Google Scholar 

  • Kugler J, Oswald WD, Herzfeld U, Seus R, Pingel J, Welzel D (1978): Langzeittherapie altersbedingter Insuffizienzerscheinungen des Gehirns. Dtsch Med Wochenschr 103: 456–462.

    Article  PubMed  CAS  Google Scholar 

  • Lopez-Arrieta JM, Birks J (2002): Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2002; (3): CD000147.

    Google Scholar 

  • Loy C, Schneider L (2006): Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD001747.

    Google Scholar 

  • Marin DB, Davis KL (1995): Experimental therapeutics. In: Bloom FE, Kupfer DJ (eds): Psychopharmacology: The fourth generation of progress. Raven Press Ltd, New York, pp 1417–1426.

    Google Scholar 

  • McShane R, Areosa Sastre A, Minakaran N (2006): Memantine for dementia. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003154.

    Google Scholar 

  • Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R et al (2000): Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 283: 1007–1015.

    Article  PubMed  CAS  Google Scholar 

  • National Institute for Health and Clinical Excellence (2006): NICE technology appraisal guidance 111: Donepezil, galantamine, rivastigmine (review) andmemantine for the treatment of Alzheimer’s disease. Includes a review of NICE technology appraisal guidance 19. Im Internet: http://guidance.nice. org.uk/TAlll/ guidance/pdf/English

    Google Scholar 

  • Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weiler RO (2003): Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nature Med 9: 448–452.

    Article  PubMed  CAS  Google Scholar 

  • Olin J, Schneider L, Novit A, Luczak S (2001): Hydergine for dementia. Cochrane Database Syst Rev. 2001;(2):CD000359.

    Google Scholar 

  • Orgogozo J-M, Gilman S, Dartigues JE, Laurent B, Puel M, Kirby LC et al. (2003): Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46–54.

    PubMed  CAS  Google Scholar 

  • Ortho-McNeil Neurologics (2005): Important Prescribing Information 31.03.2005. Internet: http://www.fda.gov/medwatch/SAFETY/2005/reminylDDLmarch.pdf

    Google Scholar 

  • Pantoni L, del Ser T, Soglian AG, Amigoni S, Spadari G, Binelli D, Inzitari D (2005): Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke 36: 619–624.

    Article  PubMed  CAS  Google Scholar 

  • Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ (2005): Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352: 2379–2388.

    Article  PubMed  CAS  Google Scholar 

  • Reines SA, Block GA, Morris JC, Liu G, Nessly ML et al (2004): Rofecoxib. No effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology 62: 66–71.

    PubMed  CAS  Google Scholar 

  • Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M et al for the Members of the Alzheimer’s Disease Cooperative Study (1997): A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 336: 1216–1222.

    Article  PubMed  CAS  Google Scholar 

  • Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB Ockene JK et al for the WHIMS Investigators (2003): Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 289: 2651–2662.

    Article  PubMed  CAS  Google Scholar 

  • Thompson TL II, Filley CM, Mitchell WD, Culig KM, LoVerde M, Byyny RL (1990): Lack of efficacy of hydergine in patients with Alzheimer’s disease. N Engl J Med 323:445–448.

    PubMed  Google Scholar 

  • Walker LC, Ibegbu CC, Todd CW, Robinson HL, Jucker M, LeVine H 3rd, Gandy S (2005): Emerging prospects for the disease-modifying treatment of Alzheimer’s disease. Biochem Pharmacol 69: 1001–1008.

    Article  PubMed  CAS  Google Scholar 

  • Winblad B (2005): Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev 11: 169–182.

    PubMed  CAS  Google Scholar 

  • Winblad B, Poritis N (1999): Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriat Psychiatry 14: 135–146.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Prof. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK Schleswig-Holstein Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Schwabe, U. (2008). Antidementiva. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2007. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72548-0_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-72548-0_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-72547-3

  • Online ISBN: 978-3-540-72548-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation